Hiroji Iwata, Norikazu Masuda, Yasuaki Sagara, Takayuki Kinoshita, Seigo Nakamura, Yasuhiro Yanagita, Reiki Nishimura, Hirotaka Iwase, Shunji Kamigaki, Hiroyuki Takei, Hitoshi Tsuda, Nobuya Hayashi and Shinzaburo Noguchi Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer Cancer 119
Version of Record online: 12 SEP 2012 | DOI: 10.1002/cncr.27818
The authors assess correlations between the expression of Ki-67 nuclear antigen Ki-67; tumor and histopathologic responses, and hormone receptor status in premenopausal patients with early stage breast cancer who receive either anastrozole plus goserelin or tamoxifen plus goserelin before undergoing surgery. The best overall tumor response is better with anastrozole compared with tamoxifen among patients who have baseline Ki-67 index scores of either ≥20% or <20%.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field